Its down 0.13, from 1.13 in 2017Q2. 61 funds opened positions while 147 raised stakes.
Currently Tetraphase Pharmaceu (NASDAQ:TTPH)'s shares owned by insiders are 0.4%, whereas shares owned by institutional owners are 63.7%. (NASDAQ:TTPH), with 7 analysts believing it is a strong buy. Schwab Charles Investment Management Inc. boosted its stake in Tetraphase Pharmaceuticals by 0.7% in the 2nd quarter. Cullen Frost Bankers Inc has 5,506 shares for 0.01% of their portfolio. Goldman Sachs Grp reported 47,051 shares. Millennium Management LLC now owns 2,715,025 shares of the biopharmaceutical company's stock valued at $17,105,000 after acquiring an additional 639,467 shares during the period. Institutional investors and hedge funds own 58.28% of the company's stock. Montag A And Assocs owns 23,310 shares for 0.1% of their portfolio. The California-based Parallax Volatility Advisers Ltd Partnership has invested 0% in Tetraphase Pharmaceuticals, Inc. Bancorp Of New York Mellon owns 235,309 shares for 0% of their portfolio.
Moving average of Tetraphase Pharmaceuticals, Inc. 15,608 are owned by Sg Americas Secs Limited Com. Needham downgraded Tetraphase Pharmaceuticals, Inc. (NYSE:DHI). Parametric Portfolio Associate Limited Liability has invested 0.06% in D.R. Horton, Inc. D L Carlson Invest Group has 0.8% invested in D.R. Horton, Inc. (NASDAQ:TTPH) or 935,000 shares. Fmr Limited Liability Company accumulated 1.29 million shares.
Since August 17, 2017, it had 0 insider purchases, and 3 selling transactions for $203,932 activity.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) had its price target lowered by Stifel Nicolaus from $13.00 to $6.00 in a report published on Wednesday, Marketbeat Ratings reports. The firm earned "Outperform" rating on Thursday, October 5 by BMO Capital Markets.
In related news, insider Jacques Dumas sold 8,750 shares of Tetraphase Pharmaceuticals stock in a transaction that occurred on Tuesday, January 30th. Therefore 40% are positive. The stock hit its twelve month high on 03/31/17, and twelve month low on 02/14/18. Two analysts have rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. Tetraphase Pharmaceuticals had 29 analyst reports since August 6, 2015 according to SRatingsIntel. Company fiscal year is ending in December and analysts' consensus recommendation is Hold for ABX and estimated EPS for next quarter is 0.20. (NASDAQ:TTPH) to report -2.87 EPS and has got OUTPERFORM rating from 4 of Thomson Reuters analysts and 0 analyst (s) given UNDERPERFORM rating. As per Thursday, November 19, the company rating was upgraded by SunTrust. This rating score is based on a 1-5 scale where a 5 would reveal a Strong Sell, a 4 indicates a Sell, 3 would equal to a hold, 2 means a Buy, and a rating of 1 would display a Strong Buy.
However, "While we consider this event a material negative event for TTPH and thus lower our price target from $11 to $6, we remind investors of the continued market opportunity for eravacycline in complicated intra-abdominal infection (cIAI), for which decisions on USA and European regulatory filings are expected in 2H18, and thus reiterate our Buy rating". Nomura downgraded Tetraphase Pharmaceuticals, Inc. The company was downgraded on Wednesday, September 9 by Cantor Fitzgerald. The stock has "Neutral" rating by Nomura on Wednesday, September 9. Stifel Nicolaus maintained the stock with "Hold" rating in Wednesday, August 9 report. As per Wednesday, July 26, the company rating was maintained by BMO Capital Markets.
The stock decreased 0.88% or $0.29 during the last trading session, reaching $32.67. Volume is simply the number of shares or contracts that trade over a given period of time, usually a day.
Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) received a Buy rating from 1 analysts. It has outperformed by 89.88% the S&P500.
Several analysts have released their opinion on Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) to report earnings on March, 14. After $-0.63 actual EPS reported by Tetraphase Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 1.59 % negative EPS growth.
Tetraphase Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company has market cap of $2.23 billion. The Company's lead product candidate is eravacycline, an intravenous and oral antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.